Journal: Scientific Reports

Article Title: Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model

doi: 10.1038/s41598-022-16077-7

Figure Lengend Snippet: Trifluridine decreases viability and increases release of ICD markers in vitro. ( A ) Viability indirectly measured by image based GFP quantification (n = 9) and ( B ) Apoptotic Index determined by Annexin V (number of Annexin V positive cells/number of GFP expressing cells) (n = 6) in HCT116-GFP monoculture and co-culture with human PBMCs, treated with DMSO vehicle (0.1%), oxaliplatin (OXP) (10 μM), or trifluridine (FTD) (3, 10 μM) for 72 h. ( C ) ATP measured by CellTiter Glo in supernatants of HCT116-GFP monoculture treated for 48 h (n = 6) and ( D ) HMGB1 measured by ELISA in supernatants of HCT116-GFP monoculture treated for 72 h. Data normalized against total number of cells per sample. Results are shown as mean ± SD from two ( B – D ) or three ( A ) independent experiments. Compared to DMSO vehicle, P ≤ 0.05 (One-way Anova with Dunnett’s multiple comparison test) for all treatment data sets except the ones marked ns, not significant.

Article Snippet: Apoptosis was measured by detection of phosphatidylserine exposed on the extracellular surface using Annexin V Red Dye (Essen Bioscience).

Techniques: In Vitro, Expressing, Co-Culture Assay, Enzyme-linked Immunosorbent Assay, Comparison